Table 1 Summary of clinical studies of stem cell therapy on keratoconus
From: Mini review: human clinical studies of stem cell therapy in keratoconus
Author(Year) | Participant characteristics | Conclusions |
|---|---|---|
Intrastromal implantation of stem cells alone: 5 eyes of 5 patients with advanced keratoconus, F/U: 3 years | Side effects: no evidences in examination | |
BCVA: 0.18 lines in Log MAR scale | ||
Sph refraction: 1.1D improvement | ||
Cyl refraction: 0.50D improvement | ||
Max keratometry: 2.0 D improvement | ||
CCT: 30 μm increase | ||
Aberrometry findings: significantly reduced | ||
Density of stromal keratocytes: increased | ||
Intrastromal implantation of decellularized stromal scaffold: 5 eyes of 5patients with advanced keratoconus, F/U:3 years | Side effects: no evidences in examination | |
BCVA: 0.18 lines in Log MAR scale | ||
Sph refraction: 1.0D improvement | ||
Cyl refraction: 1.50D improvement | ||
Max. keratometry: 2.0 D improvement | ||
CCT: 31 μm increase | ||
Aberrometry findings: significantly reduced | ||
Intrastromal implantation of stem cells with a decellularized stromal scaffold: 4 eyes of 4 patients with advanced keratoconus, F/U:3 years | Side effects: no evidences in examination | |
BCVA: 0.19 lines in Log MAR scale | ||
Sph refraction: 1.2D improvement | ||
Cyl refraction: 1.1D improvement | ||
Max. keratometry: 2.0 D improvement | ||
CCT: 30 μm increase | ||
Aberrometry findings: significantly reduced | ||
Density of stromal keratocytes: increased | ||
Intrastromal implantation of stem cells alone: | Side effects: no evidences in examination | |
8 eyes of 8 patients with moderate to severe keratoconus, age:22–35 years, F/U: 6 months | BCVA: 1.85 lines in Snellen scale | |
Sph refraction: 0.34D improvement | ||
Cyl refraction: 0.84D improvement | ||
Ant. keratometry: 0.76D improvement | ||
CCT: 6.29 μm increase | ||
Aberrometry findings: reduced | ||
Density of stromal keratocytes: increased | ||
1 eye with severe keratoconus and central corneal scaring, age: 65 years, F/U: 6 months | Side effects: no evidences in examination | |
BCVA: improvement of visual acuity from HM to 20/80 in Snellen scale | ||
Sph & Cyl refraction: marked improvement | ||
Keratometry: marked improvement | ||
CCT: marked improvement | ||
Aberrometry findings: marked reduced | ||
Density of stromal keratocytes: increased |